R391
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 129
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.490
- PROTEIN_SECRETION+0.430
- G2M_CHECKPOINT+0.400
- PANCREAS_BETA_CELLS+0.380
- MITOTIC_SPINDLE+0.250
- MYC_TARGETS_V1+0.230
- FATTY_ACID_METABOLISM+0.220
- SPERMATOGENESIS+0.200
- ANDROGEN_RESPONSE+0.190
- MTORC1_SIGNALING+0.140
Top 10 suppressed
- ANGIOGENESIS-0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- WNT_BETA_CATENIN_SIGNALING-0.400
- ALLOGRAFT_REJECTION-0.370
- COAGULATION-0.360
- P53_PATHWAY-0.340
- INFLAMMATORY_RESPONSE-0.310
- MYOGENESIS-0.310
- NOTCH_SIGNALING-0.290
- TNFA_SIGNALING_VIA_NFKB-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R356 | — | — | 0.925 |
| 2 | R288 | — | — | 0.916 |
| 3 | SRR12202430 | — | — | 0.897 |
| 4 | R320 | — | — | 0.893 |
| 5 | R150 | — | — | 0.884 |
| 6 | SRR1797285 | — | cohortSC | 0.879 |
| 7 | DRR168591 | — | — | 0.877 |
| 8 | SRR1797279 | — | cohortSC | 0.875 |
| 9 | SRR12202425 | — | — | 0.864 |
| 10 | TCGA-62-A46O-01A-11R-A24H-07 | — | cohortA4 | 0.856 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.380 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.140 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.130 | Remibrutinib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.040 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.020 | Inavolisib | — uncovered |